Biotech 2024: Opportunities and challenges for Israeli companies
As we step into 2024, the Israeli biotech sector is at a pivotal moment, eagerly anticipating a shift after a challenging two-year period.
“Despite their strong clinical data and established R&D programs, Israeli biotech companies are undervalued. Following two years of economic downturn, these companies now present attractive investment opportunities,” writes Dr. Tomer Bronshtein, VP for Innovation and Corporate Development at Bonus Biogroup.
Read more in the Calcalist feature.
Meanwhile, venture capital firm Red Dot Capital Partners announced the first closing of its third fund. The fund, which is planned to total USD250 million, is intended for investment in Israeli startups at stages A to C, that is, in early growth rounds.
The firm says it has commitments from investors of over USD200 million, and that it is already examining potential initial investments in local companies. It invests in companies with revenue of USD1-5 million, in almost all areas of technology, apart from healthcare, medical devices, pharmaceuticals and biotech. Read more in Calcalist.
